{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-099872","form_type":"8-K","ticker":"NVCT","cik":"0001875558","company_name":"Nuvectis Pharma, Inc.","filed_at":"2023-09-12T23:59:59+00:00","discovered_at":"2026-05-14T18:03:35.959331+00:00","generated_at":"2026-06-10T21:23:51.892214+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Nuvectis Pharma initiates Phase 1a trial of NXP900 for advanced solid tumors","bullets":["Phase 1a dose-escalation study evaluates safety, tolerability, and PK of NXP900 in advanced solid tumor patients.","NXP900 is a novel SRC/YES1 kinase inhibitor with low nanomolar IC50 (YES1: 0.5nM, SRC: 2.4nM).","Preclinical models showed robust single-agent anti-cancer activity across several solid tumor types.","CEO Ron Bentsur highlights NXP900's unique mechanism and target specificity versus multi-kinase inhibitors."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-099872","json":"https://secwatch.observer/filing/0001104659-23-099872.json","markdown":"https://secwatch.observer/filing/0001104659-23-099872.md","text":"https://secwatch.observer/filing/0001104659-23-099872.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1875558/000110465923099872/0001104659-23-099872-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1875558/000110465923099872/tm2325910d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-10T21:23:51.892214+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}